Some implications of melatonin use in chronopharmacology of insomnia

Autores
Golombek, Diego A.; Pandi Perumal, Seithikurippu R.; Brown, Gregory M.; Cardinali, Daniel Pedro
Año de publicación
2015
Idioma
inglés
Tipo de recurso
artículo
Estado
versión enviada
Descripción
Fil: Golombek, Diego A. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología; Argentina
Fil: Golombek, Diego A. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Pandi Perumal, Seithikurippu R. Somnogen Canada Inc; Canadá
Fil: Brown, Gregory M. University of Toronto. Centre for Addiction and Mental Health; Canadá
Fil: Cardinali, Daniel P. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas. Instituto de Investigaciones Biomédicas; Argentina
Fil: Cardinali, Daniel P. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas. Departamento de Docencia e Investigación; Argentina
Abstract: The last decade has witnessed the emergence of new chronopharmacological perspectives. In the case of sleep, accumulating evidence suggests that even a minor dysfunction in the biological clock can impact upon body physiology causing increases in sleep onset latency, phase delays or advances in sleep initiation, frequent nocturnal awakenings, reduced sleep efficiency, delayed and shortened rapid eye movement sleep and increased periodic leg movements. Thus, restoration of the adequate circadian pattern of by proper sleep hygiene, targeted exposure to light and the use of chronobiotic drugs, such as melatonin, which affect the output phase of clock-controlled circadian rhythms, can help to recover the sleep-wake cycle. The optimization of drug effects and/or minimization of toxicity by timing medications with regard to biological rhythms is known as chronotherapeutics. While chronotherapeutical approaches have been particularly successful in the treatment of hypertension, allergies and some forms of cancer, a time-dependent pharmacological approach can be also effective when dealing with sleep disruptions like insomnia. A large proportion of patients under benzodiazepine (BZD)/Z drug treatment fail to achieve a complete and sustained recovery and are left with residual symptoms, like tolerance or dependency, that make relapse or recurrence more likely, and poorer quality of life a reality. Thus the chronic and extensive use of BZD/Z drugs has become a public health issue and has led to multiple campaigns to reduce both prescription and consumption of BZD/Z-drugs. This short review discusses available data on the efficacy of melatonin to reduce chronic BZD use in insomnia patients.
Fuente
Preprint del documento publicado en European Journal of Pharmacology Vol. 762, 2015
ISSN 1879-0712 (online)
ISSN 0014-2999 (impreso)
Materia
MEDICINA
RITMO CIRCADIANO
SUEÑO
MELATONINA
INSOMNIO
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/4.0/
Repositorio
Repositorio Institucional (UCA)
Institución
Pontificia Universidad Católica Argentina
OAI Identificador
oai:ucacris:123456789/1459

id RIUCA_63de13c45d3fd2b2beda3580be040c4b
oai_identifier_str oai:ucacris:123456789/1459
network_acronym_str RIUCA
repository_id_str 2585
network_name_str Repositorio Institucional (UCA)
spelling Some implications of melatonin use in chronopharmacology of insomniaGolombek, Diego A.Pandi Perumal, Seithikurippu R.Brown, Gregory M.Cardinali, Daniel PedroMEDICINARITMO CIRCADIANOSUEÑOMELATONINAINSOMNIOFil: Golombek, Diego A. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología; ArgentinaFil: Golombek, Diego A. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Pandi Perumal, Seithikurippu R. Somnogen Canada Inc; CanadáFil: Brown, Gregory M. University of Toronto. Centre for Addiction and Mental Health; CanadáFil: Cardinali, Daniel P. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas. Instituto de Investigaciones Biomédicas; ArgentinaFil: Cardinali, Daniel P. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas. Departamento de Docencia e Investigación; ArgentinaAbstract: The last decade has witnessed the emergence of new chronopharmacological perspectives. In the case of sleep, accumulating evidence suggests that even a minor dysfunction in the biological clock can impact upon body physiology causing increases in sleep onset latency, phase delays or advances in sleep initiation, frequent nocturnal awakenings, reduced sleep efficiency, delayed and shortened rapid eye movement sleep and increased periodic leg movements. Thus, restoration of the adequate circadian pattern of by proper sleep hygiene, targeted exposure to light and the use of chronobiotic drugs, such as melatonin, which affect the output phase of clock-controlled circadian rhythms, can help to recover the sleep-wake cycle. The optimization of drug effects and/or minimization of toxicity by timing medications with regard to biological rhythms is known as chronotherapeutics. While chronotherapeutical approaches have been particularly successful in the treatment of hypertension, allergies and some forms of cancer, a time-dependent pharmacological approach can be also effective when dealing with sleep disruptions like insomnia. A large proportion of patients under benzodiazepine (BZD)/Z drug treatment fail to achieve a complete and sustained recovery and are left with residual symptoms, like tolerance or dependency, that make relapse or recurrence more likely, and poorer quality of life a reality. Thus the chronic and extensive use of BZD/Z drugs has become a public health issue and has led to multiple campaigns to reduce both prescription and consumption of BZD/Z-drugs. This short review discusses available data on the efficacy of melatonin to reduce chronic BZD use in insomnia patients.Elsevier2015info:eu-repo/semantics/articleinfo:eu-repo/semantics/submittedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfhttps://repositorio.uca.edu.ar/handle/123456789/14591879-0712 (online)0014-2999 (impreso)10.1016/j.ejphar.2015.05.03226004526Golombek D. A., et al. Some implications of melatonin use in chronopharmacology of insomnia [en línea]. Preprint del documento publicado en European Journal of Pharmacology. 2015, 762. doi:10.1016/j.ejphar.2015.05.032. Disponible en: https://repositorio.uca.edu.ar/handle/123456789/1459Preprint del documento publicado en European Journal of Pharmacology Vol. 762, 2015ISSN 1879-0712 (online)ISSN 0014-2999 (impreso)reponame:Repositorio Institucional (UCA)instname:Pontificia Universidad Católica Argentinaengenginfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/4.0/2025-07-03T10:55:17Zoai:ucacris:123456789/1459instacron:UCAInstitucionalhttps://repositorio.uca.edu.ar/Universidad privadaNo correspondehttps://repositorio.uca.edu.ar/oaiclaudia_fernandez@uca.edu.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:25852025-07-03 10:55:17.932Repositorio Institucional (UCA) - Pontificia Universidad Católica Argentinafalse
dc.title.none.fl_str_mv Some implications of melatonin use in chronopharmacology of insomnia
title Some implications of melatonin use in chronopharmacology of insomnia
spellingShingle Some implications of melatonin use in chronopharmacology of insomnia
Golombek, Diego A.
MEDICINA
RITMO CIRCADIANO
SUEÑO
MELATONINA
INSOMNIO
title_short Some implications of melatonin use in chronopharmacology of insomnia
title_full Some implications of melatonin use in chronopharmacology of insomnia
title_fullStr Some implications of melatonin use in chronopharmacology of insomnia
title_full_unstemmed Some implications of melatonin use in chronopharmacology of insomnia
title_sort Some implications of melatonin use in chronopharmacology of insomnia
dc.creator.none.fl_str_mv Golombek, Diego A.
Pandi Perumal, Seithikurippu R.
Brown, Gregory M.
Cardinali, Daniel Pedro
author Golombek, Diego A.
author_facet Golombek, Diego A.
Pandi Perumal, Seithikurippu R.
Brown, Gregory M.
Cardinali, Daniel Pedro
author_role author
author2 Pandi Perumal, Seithikurippu R.
Brown, Gregory M.
Cardinali, Daniel Pedro
author2_role author
author
author
dc.subject.none.fl_str_mv MEDICINA
RITMO CIRCADIANO
SUEÑO
MELATONINA
INSOMNIO
topic MEDICINA
RITMO CIRCADIANO
SUEÑO
MELATONINA
INSOMNIO
dc.description.none.fl_txt_mv Fil: Golombek, Diego A. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología; Argentina
Fil: Golombek, Diego A. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Pandi Perumal, Seithikurippu R. Somnogen Canada Inc; Canadá
Fil: Brown, Gregory M. University of Toronto. Centre for Addiction and Mental Health; Canadá
Fil: Cardinali, Daniel P. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas. Instituto de Investigaciones Biomédicas; Argentina
Fil: Cardinali, Daniel P. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas. Departamento de Docencia e Investigación; Argentina
Abstract: The last decade has witnessed the emergence of new chronopharmacological perspectives. In the case of sleep, accumulating evidence suggests that even a minor dysfunction in the biological clock can impact upon body physiology causing increases in sleep onset latency, phase delays or advances in sleep initiation, frequent nocturnal awakenings, reduced sleep efficiency, delayed and shortened rapid eye movement sleep and increased periodic leg movements. Thus, restoration of the adequate circadian pattern of by proper sleep hygiene, targeted exposure to light and the use of chronobiotic drugs, such as melatonin, which affect the output phase of clock-controlled circadian rhythms, can help to recover the sleep-wake cycle. The optimization of drug effects and/or minimization of toxicity by timing medications with regard to biological rhythms is known as chronotherapeutics. While chronotherapeutical approaches have been particularly successful in the treatment of hypertension, allergies and some forms of cancer, a time-dependent pharmacological approach can be also effective when dealing with sleep disruptions like insomnia. A large proportion of patients under benzodiazepine (BZD)/Z drug treatment fail to achieve a complete and sustained recovery and are left with residual symptoms, like tolerance or dependency, that make relapse or recurrence more likely, and poorer quality of life a reality. Thus the chronic and extensive use of BZD/Z drugs has become a public health issue and has led to multiple campaigns to reduce both prescription and consumption of BZD/Z-drugs. This short review discusses available data on the efficacy of melatonin to reduce chronic BZD use in insomnia patients.
description Fil: Golombek, Diego A. Universidad Nacional de Quilmes. Departamento de Ciencia y Tecnología; Argentina
publishDate 2015
dc.date.none.fl_str_mv 2015
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/submittedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str submittedVersion
dc.identifier.none.fl_str_mv https://repositorio.uca.edu.ar/handle/123456789/1459
1879-0712 (online)
0014-2999 (impreso)
10.1016/j.ejphar.2015.05.032
26004526
Golombek D. A., et al. Some implications of melatonin use in chronopharmacology of insomnia [en línea]. Preprint del documento publicado en European Journal of Pharmacology. 2015, 762. doi:10.1016/j.ejphar.2015.05.032. Disponible en: https://repositorio.uca.edu.ar/handle/123456789/1459
url https://repositorio.uca.edu.ar/handle/123456789/1459
identifier_str_mv 1879-0712 (online)
0014-2999 (impreso)
10.1016/j.ejphar.2015.05.032
26004526
Golombek D. A., et al. Some implications of melatonin use in chronopharmacology of insomnia [en línea]. Preprint del documento publicado en European Journal of Pharmacology. 2015, 762. doi:10.1016/j.ejphar.2015.05.032. Disponible en: https://repositorio.uca.edu.ar/handle/123456789/1459
dc.language.none.fl_str_mv eng
eng
language eng
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/4.0/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/4.0/
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv Preprint del documento publicado en European Journal of Pharmacology Vol. 762, 2015
ISSN 1879-0712 (online)
ISSN 0014-2999 (impreso)
reponame:Repositorio Institucional (UCA)
instname:Pontificia Universidad Católica Argentina
reponame_str Repositorio Institucional (UCA)
collection Repositorio Institucional (UCA)
instname_str Pontificia Universidad Católica Argentina
repository.name.fl_str_mv Repositorio Institucional (UCA) - Pontificia Universidad Católica Argentina
repository.mail.fl_str_mv claudia_fernandez@uca.edu.ar
_version_ 1836638330142326784
score 13.13397